Free Trial
NASDAQ:ICU

SeaStar Medical Q4 2023 Earnings Report

SeaStar Medical logo
$1.24 +0.08 (+6.90%)
Closing price 04:00 PM Eastern
Extended Trading
$0.67 -0.57 (-46.05%)
As of 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SeaStar Medical EPS Results

Actual EPS
-$4.75
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

SeaStar Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SeaStar Medical Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Wednesday, April 17, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

SeaStar Medical's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 3:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

SeaStar Medical Earnings Headlines

Arizona-made nanochips the new millionaire maker?
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
See More SeaStar Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SeaStar Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SeaStar Medical and other key companies, straight to your email.

About SeaStar Medical

SeaStar Medical (NASDAQ:ICU), Inc. (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR. TriGUARD 3 features an advanced frame and filter design that conforms to varying patient anatomies, enabling physicians to position the device safely and effectively without obstructing critical arterial access routes. SeaStar Medical continues to invest in clinical trials and registry studies to demonstrate the safety and performance of its technology and to support regulatory clearances in North America, Europe and other key markets.

Headquartered in Kansas City, Missouri, SeaStar Medical serves a global customer base through direct sales and distribution partnerships in Europe and parts of Asia Pacific, in addition to its U.S. operations. The company collaborates with interventional cardiologists, cardiac surgeons and research institutions to refine device design and expand indications. Its leadership team brings extensive experience from leading cardiovascular and medical device firms, guiding SeaStar Medical through product development, regulatory interactions and market introduction efforts to address the growing demand for neuroprotection in structural heart care.

View SeaStar Medical Profile

More Earnings Resources from MarketBeat